Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol 2010 Feb;42(2):186-92

Date

11/17/2009

Pubmed ID

19914392

Pubmed Central ID

PMC2818495

DOI

10.1016/j.biocel.2009.11.001

Scopus ID

2-s2.0-73749083118   19 Citations

Abstract

Prostate cancer is the most common non-cutaneous cancer in Western males. The majority of prostate cancer fatalities are caused by development of castration-resistant growth and metastatic spread of the primary tumor. The average duration of the response of primary prostate cancer to hormonal ablation is less than 3 years, and 75% of prostate cancers in the United States progress to castration-resistant disease. The existing pharmacological therapies for metastatic and/or castration-resistant prostate cancer do not provide significant survival benefit. This review summarizes the importance of transcription factor Stat5 signaling in the pathogenesis of prostate cancer and discusses the molecular basis of Stat5a/b inhibition as a therapeutic strategy for prostate cancer.

Author List

Liao Z, Lutz J, Nevalainen MT

Author

Marja T. Nevalainen MD, PhD Assistant Dean, Professor in the Pathology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Antineoplastic Agents
Disease Progression
Drug Discovery
Humans
Male
Prostatic Neoplasms
STAT5 Transcription Factor
Signal Transduction
jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473